MetaCap

Adicet Bio (ACET) vs IGC Pharma (IGC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IGC Pharma (IGC) has outperformed Adicet Bio (ACET) over the past year, losing 47.5% versus a loss of 77.8%. Over five years, IGC leads with a -87.6% price change compared with -98.6% for ACET. Adicet Bio is the larger company by market cap ($20.0 million vs $19.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACET-77.78%IGC-47.50%
+14%-34%-82%
Nov 21, 20251 yearNov 20, 2026
ACET-98.56%IGC-88.25%
+140%+15%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACET versus IGC key metrics
MetricACETIGC
Share price$2.14$0.168
Market cap$20.03M$19.60M
1-day change-13.01%-8.70%
YTD return-74.58%-40.00%
1-year return-77.78%-47.50%
5-year return-98.58%-87.65%
EPS (TTM)$-7.53$-0.07
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.27M
Revenue growth (YoY)—-5.50%
Net income (latest FY)$-116.80M$-7.12M
Gross margin—48.70%
Operating margin—-585.84%
Net margin—-560.35%
52-week high$11.15$0.36
52-week low$2.12$0.08
Distance from 52-week high-80.81%-53.33%
Analyst consensusstrong_buynone
Avg. price target upside+1527.57%+3471.43%
Average volume271.05K615.25K
Shares outstanding9.36M116.69M
Employees10270
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IGC has outperformed ACET by 30.3 percentage points over the past year.

About Adicet Bio

ACET stock →

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees

About IGC Pharma

IGC stock →

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

ACET vs IGC FAQ

Which is bigger, Adicet Bio or IGC Pharma?

Adicet Bio (ACET) is larger, with a market capitalization of $20.03M compared with $19.60M for IGC Pharma (IGC).

Which stock has performed better over the past year, ACET or IGC?

IGC returned -47.50% over the past 12 months, compared with -77.78% for ACET (price return, excluding dividends). Past performance does not predict future results.

Are Adicet Bio and IGC Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons